Gelesis
Gelesis is a biotechnology company, which has developed a novel hydrogel platform technology to treat obesity and is developing therapies for other chronic diseases related to the gastrointestinal (GI) tract
Investment Facts
Gelesis
Gelesis is a biotechnology company, which has developed a novel hydrogel platform technology to treat obesity and is developing therapies for other chronic diseases related to the gastrointestinal (GI) tract
Key facts
- Sales Not Disclosed
- Employees c. 60
- Industry Life Sciences & Healthcare
- Headquarters North America
- Geographic Footprint Europe, North America
- Website www.gelesis.com
- Investment Date December 2019
- Fund VIP III Cortex
- Gelesis’ first product, Plenity, is FDA-approved and is expected to launch in the US in 2020
- Plenity aids weight management in overweight and obese adults with a Body Mass Index (BMI) of 25-40 kg/m2
- In clinical studies, Plenity showed a unique combination of effectiveness combined with a favourable safety profile
- In the US, Gelesis recently entered into a partnership with Ro, a leading telehealth provider, to offer high-quality remote care
- Additionally, Gelesis is developing its investigational candidates for type 2 diabetes and prediabetes, non-alcoholic steatohepatitis (NASH) and Chronic Idiopathic Constipation (CIC)